Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Enliven Therapeutics and increased the price target to $38.00 from $37.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky’s rating is based on several promising developments within Enliven Therapeutics. The company reported strong financial health with $490.5 million in cash and equivalents, which is expected to sustain operations into the first half of 2029, surpassing the anticipated pivotal Phase 3 data for their CML treatment. This financial stability provides a solid foundation for future growth and development.
Furthermore, the updated Phase 1 data for ELVN-001, a treatment for chronic myeloid leukemia, demonstrated impressive efficacy and safety results. The treatment showed a significant major molecular response rate and favorable safety profile compared to other CML treatments. Enliven’s plans to initiate a pivotal study in 2026, potentially in a larger patient population, further supports the potential for ELVN-001 to become a key treatment option in the CML market, which is projected to be substantial. These factors collectively underpin Slutsky’s Buy rating for Enliven Therapeutics.
In another report released today, BTIG also reiterated a Buy rating on the stock with a $45.00 price target.